Peanut-specific T-cell receptor (Peanut-specific TCR)

Peanut-specific T-cell receptors (TCRs) are specialized protein complexes located on the surface of T lymphocytes that specifically recognize and bind to peanut allergen peptides, such as those derived from Ara h 1, Ara h 2, Ara h 3, and Ara h 6, when presented by Major Histocompatibility Complex (MHC) class II molecules [1.1.3, 1.2.1]. In individuals with peanut allergies, these TCRs are predominantly expressed by Th2-polarized CD4+ memory T cells, which orchestrate the allergic immune response by secreting pro-inflammatory cytokines (IL-4, IL-5, IL-13) and promoting the production of peanut-specific IgE by B cells [1.2.3, 1.5.2]. These receptors serve as a primary therapeutic target for allergen-specific immunotherapies (AIT), including oral immunotherapy (OIT) and novel peptide-based vaccines like PVX108, which aim to reprogram the immune system toward a state of clinical tolerance [1.1.2, 1.2.4]. Therapeutic intervention typically involves the gradual exposure to allergens or specific epitopes to induce T-cell anergy, the deletion of pathogenic Th2 effector cells, or the expansion of peanut-specific regulatory T cells (Tregs) that suppress allergic inflammation [1.1.1, 1.2.5]. Monitoring the TCR repertoire and the phenotypic shifts in peanut-reactive T cells is essential for evaluating the efficacy of desensitization treatments and identifying patients at risk for severe systemic reactions or complications like eosinophilic esophagitis [1.1.4, 1.4.2].

Other names

Ara h 1-specific T-cell receptorAra h 2-specific T-cell receptorAra h 3-specific T-cell receptorAra h 6-specific T-cell receptorPeanut allergen-specific T-cell receptorPeanut-reactive T-cell receptor

Induction of immune tolerance through T-cell desensitization, anergy, or deletion of pathogenic Th2 clones, and the expansion of allergen-specific regulatory T cells (Tregs).